The pharmacology of ergotamine and dihydroergotamine

Headache

Volumn 37, Issue SUPPL. 1, 1997, Pages

  Silberstein, Stephen D ^a  

^a Germantown Hosp and Medical Center   (United States)

Author keywords

dihydroergotamine (DHE); ergotamine tartrate (ET); migraine

Indexed keywords

DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR;

CONFERENCE PAPER; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HISTORY OF MEDICINE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECTAL DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; VASOCONSTRICTION;

ANALGESICS, NON-NARCOTIC; BODY FLUIDS; DIHYDROERGOTAMINE; ERGOTAMINE; HUMANS; MIGRAINE DISORDERS; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031025119     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. Rutschmann J, Stadler PA. Chemical background. In: Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. New York: Springer-Verlag; 1978:29-85.
2. Berde B, Stürmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. New York: Springer-Verlag; 1978:1-28.
3. Clark BJ, Chu D, Aellig WH. Actions on the heart and circulation. In: Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. New York: Springer Verlag; 1978:321-420.
4. Eadie MT. Ergotamine pharmacokinetics in man: an editorial. Cephalalgia. 1983;3:135-138.
5. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Neurology. 1995;45:585-587.
6. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology. 1995;45:577-584.
7. Stevens AA. Modern Materia Medica and Therapeutics. 4th ed. Philadelphia: WB Saunders Company; 1907:248-252.
8. Rothlin E. Historical development of the ergot therapy of migraine. Int Arch Allergy. 1955;7:205-209.
9. Merhoff GC, Porter JM. Ergot intoxication: historical review and description of unusual clinical manifestations. Ann Surg. 1974;180:773-779.
10. Perrin VL. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet. 1985;10:334-352.
11. Graham JR, Wolff HG. The circulation of the brain and spinal cord. Proc Assoc Res Nerv Ment Dis. 1937;18:638.
12. Norton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc. 1945;20:241-248.
13. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-171.
14. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995-997.
15. Scott AK. Dihydroergotamine: a review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol. 1992;15:289-296.
16. Tfelt-Hansen P, Lipton RB. Dihydroergotamine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:323-327.
17. Müller-Schweinitzer E, Fanchamps A. Effects on arterial receptors of ergot derivatives used in migraine. Adv Neurol. 1982;33:343-356.
18. Chu D, Owen DAA, Sturmer E. Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad Med J. 1976;52(suppl 1):32-36.
19. Melander S, Nordenfelt I. Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation. Clin Sci. 1970;39:183-201.
20. Brazeau P. Ergot, ergot alkaloids, and oxytocin. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 3rd ed. New York: The Macmillan Company; 1965:878-892.
21. Müller-Schweinitzer E. Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol. 1984;26:699-705.
22. Müller-Schweinitzer E, Rosenthaler J. Dihydro-ergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol. 1987;9:686-693.
23. Müller-Schweinitzer E, Weidmann H. Basic pharmacological properties. In: Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. New York: Springer Verlag; 1978:87-232.
24. Silberstein SD. Serotonin (5-HT) and migraine. Headache. 1994;34:408-417.
25. de Marées H, Welzel D, de Marées A, Klotz U, Tiedjen KU, Knaup G. Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing. Eur J Clin Pharmacol. 1986;30:685-689.
26. Tfelt-Hansen P, Eickhoff JH, Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol. 1980;47:151-156.
27. Tfelt-Hansen P. Clinical pharmacology of ergotamine. An overview. In: Diener H-C, Wilkinson M, eds. Drug-Induced Headache. Berlin: Springer-Verlag; 1988:105-116.
28. Müller-Schweinitzer E. The recording of venous compliance in the conscious dog: a method for the assessment of veno-constrictor agents. J Pharmacol Methods. 1984;12:53-58.
29. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol. 1982;23:235-240.
30. Kanto J. Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile. Int J Clin Pharmacol Ther Toxicol. 1983;21:135-142.
31. Maurer G, Frick W. Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol. 1984;26:463-470.
32. Eckert H, Kiechel JR, Rosenthaler J, Schmidt R, Schreier E, Biopharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability. In: Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. New York: Springer-Verlag; 1978:719-803.
33. Aellig WH, Nüesch E. Comparative pharmacokinetic investigations with tritium labelled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol. 1977;15:106-112.
34. Aellig WH, Rosenthaler J. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol. 1986;30:581-584.
35. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol. 1983;16:695-699.
36. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986;30:331-334.
37. Schran HF, Schwarz HJ, Talbot KC, Loeffler LJ. Specific radioimmunoassay of ergot peptide alkaloids in plasma. Clin Chem. 1979;25:1928-1933.
38. Edlund PO. Determination of ergot alkaloids in plasma by high performance liquid chromatography and fluorescence detection. J Chromatogr. 1981;226:107-115.
39. Ala-Hurula V, Myllylä VV, Arvela P, Heikkilä J, Kärki N, Hokkanen E. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol. 1979;15:51-55.
40. Schran HF, Tse FLS, Chang C-T, et al. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res. 1994;55:1501-1508.
41. Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:313-322.
42. Ekbom K, Krabbe AE, Paalzow G, et al. Optimal routes of administration of ergotamine tartrate in cluster headache patients: a pharmacokinetic study. Cephalalgia. 1983;3:15-20.
43. Schmidt R, Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol. 1974;7:213-216.
44. Little PJ, Jennings GL, Skews H, et al. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol. 1982;13:785-790.
45. Sandoz Pharmaceuticals Corporation, East Hanover, NJ. Data on file.
46. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44:447-453.
47. Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by xenon-133 inhalation and emission tomography. Brain. 1984;107:447-461.
48. Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987;18:120-123.
49. Hachinski V, Norris JW, Edmeads J, Cooper PW. Ergotamine and cerebral blood flow. Stroke. 1978;9:594-596.
50. Diener H-C, Peters C, Rudzio M, et al. Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraineurs. J Neurol. 1991;238:245-250.
51. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin. 1990;8:801-815.
52. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol. 1988;24:732-737.
53. 3H-dihydroergotamine-binding sties in the cat central nervous system: relevance to migraine. Ann Neurol. 1991;29:91-94.
54. Lashley KS. Patterns of cerebral integration indicated by the scotomas of migraine. Arch Neurol Psychiatry. 1941;46:259-264.
55. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol. 1944;7:359-390.
56. Barkley GL, Leheta BJ, Tepley N, Gaymer J, Aboukasm A, Welch KMA. Effects of dihydroergotamine on spreading depression. In: Olesen J, Saxena PR, eds. 5-Hydroxytryptamine Mechanisms in Primary Headaches. New York: Raven Press; 1992:236-241.
57. Ala-Hurula V. Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. Eur J Clin Pharmacol. 1982;21:397-402.